Navigation Links
Amsterdam Molecular Therapeutics Reports Half-Year Results 2011
Date:8/24/2011

AMSTERDAM, The Netherlands, August 25, 2011 /PRNewswire/ --

Amsterdam Molecular Therapeutics (Euronext: AMT), a leader in the field of human gene therapy, today reported its results for the first half year of 2011.

Highlights

  • Glybera®:
    • Data showing Glybera produces significant reduction in risk of pancreatitis in LPLD patients presented at European Atherosclerosis Society Meeting
    • CHMP does not consider Glybera approvable at this time
    • Chylomicrons now validated as biomarker for Glybera efficacy; data presented at American Society of Gene and Cell Therapy annual meeting
    • AMT generating further chylomicron data from existing treated patients to support re-examination process
    • Submitted for re-examination, outcome expected before end 2011
  • Collaboration with Institut Pasteur-led Consortium to develop Sanfilippo B gene therapy product for cGMP manufactured material; worth up to € 1.8 million to AMT
  • € 1.1 million funding for Acute Intermittent Porphyria gene therapy product as part of EU Consortium
  • Grant from Dutch Parents Association for Duchenne Muscular Dystrophy gene therapy
  • Appointment of Dr. Carlos R. Camozzi as Chief Medical Officer
  • Key financial figures in line with guidance
  • Cash & cash equivalents of € 9.1 million at June 30, 2011, in line with budget

"We have moved quickly and have already filed an application for re-examination of Glybera, after the initial disappointment with the CHMP opinion in June. We are continuing to collect more data to show that there is a long-term reduction in the incidence of pancreatitis in treated patients.  We will be able to generate the additional data required from the existing treated patients, and the data will come from a trial which we had already pla
'/>"/>

SOURCE Amsterdam Molecular Therapeutics B.V
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related biology technology :

1. Amsterdam Molecular Therapeutics Reports Half Year Results 2008
2. Amsterdam Molecular Therapeutics Reports Full Year Results 2008
3. Amsterdam Molecular Therapeutics Reports Half Year Results 2009
4. The University of Amsterdam Joins the MetaMiner Metabolic Diseases Project
5. Amsterdam Molecular Therapeutics Reports Full Year Results 2009
6. Amsterdam Molecular Therapeutics Reports Half-Year Results 2010
7. Amsterdam Molecular Therapeutics Successfully Lowers Cholesterol In Vivo With Enhanced Novel MicroRNA AAV Gene Therapy
8. Amsterdam Molecular Therapeutics Appoints Dr. Carlos R. Camozzi as Chief Medical Officer
9. Amsterdam Molecular Therapeutics Files Glybera® European Marketing Application for Re-examination
10. Molecular sleuths track evolution through the ribosome
11. VisEn Announces Commercial Launch of IntegriSenseTM Fluorescence Molecular Imaging Agent
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/30/2015)... Available in select spas in ... , Phytomer’s DOUCEUR INTEMPORELLE Restorative Shield Cream provides ... battling the weakening threat of inflammaging, aging directly ... with star ingredient GLYCOSEA, a complex of restructuring ... of soothing minerals and trace elements. GLYCOSEA works ...
(Date:4/30/2015)... (PRWEB) April 30, 2015 Clinovo ... 2015 PharmaSUG Annual Conference held in Orlando, FL ... Staffing Solutions along with Leslie Kolman, Manager of Staffing ... latest Clinovo news at Booth #17. , “We ... Conference again this year”, Says Trisha Heredia, Senior Director ...
(Date:4/29/2015)... 2015 According to a new ... Product (Portable & Non-Portable), Component (Accelerometer, Proximity Probe, ... Metal & Mining, & Others), & Geography - ... expected to reach $1,453.76 Million by 2020, at ... data tables and 92 figures spread through 205 ...
(Date:4/29/2015)... BRM) ("Biorem" or "the Company") today announced its results for the three ... financial statements and MD&A have been filed on SEDAR ( www.sedar.com ). ... 2014 , 2013 Revenue 3,968 , 5,121 ... 1,703 , 2,231 , 5,866 Operating  expenses ... , 4,562 Ebitda* 92 , 418 , ...
Breaking Biology Technology:Phytomer introduces DOUCEUR INTEMPORELLE Restorative Shield Cream 2Phytomer introduces DOUCEUR INTEMPORELLE Restorative Shield Cream 3Clinovo Exhibits at the 2015 PharmaSUG Annual Conference on May 17-20th in Orlando, FL 2Clinovo Exhibits at the 2015 PharmaSUG Annual Conference on May 17-20th in Orlando, FL 3Vibration Monitoring Equipment (Portable & Non-Portable) Market worth $1,453.76 Million by 2020 - New Report by MarketsandMarkets 2Vibration Monitoring Equipment (Portable & Non-Portable) Market worth $1,453.76 Million by 2020 - New Report by MarketsandMarkets 3Vibration Monitoring Equipment (Portable & Non-Portable) Market worth $1,453.76 Million by 2020 - New Report by MarketsandMarkets 4Biorem Reports Results for Fourth Quarter 2014 and Year Ended December 31, 2014 2Biorem Reports Results for Fourth Quarter 2014 and Year Ended December 31, 2014 3Biorem Reports Results for Fourth Quarter 2014 and Year Ended December 31, 2014 4
... Inc. (Nasdaq: AMLN ) today announced positive ... combination treatment comprising pramlintide, an analog of the natural ... hormone leptin, in overweight and obese patients. This Phase ... treatment and also provided important information to inform dose ...
... CPHD ) today announced that it will report financial results ... 30, 2009, after the close of the market. , , ... Time on Thursday, July 30, 2009, to discuss the results. ... www.cepheid.com/investors at least 15 minutes before the scheduled ...
... international ports could be the most affordable approach to ... not carrying nuclear bombs, according to a paper being ... the Institute for Operations Research and the Management Sciences ... in place that relies on targeting only a small ...
Cached Biology Technology:Amylin Pharmaceuticals Announces Positive Results from Dose-Ranging Clinical Study of Pramlintide/Metreleptin Combination Treatment for Obesity 2Amylin Pharmaceuticals Announces Positive Results from Dose-Ranging Clinical Study of Pramlintide/Metreleptin Combination Treatment for Obesity 3Amylin Pharmaceuticals Announces Positive Results from Dose-Ranging Clinical Study of Pramlintide/Metreleptin Combination Treatment for Obesity 4Amylin Pharmaceuticals Announces Positive Results from Dose-Ranging Clinical Study of Pramlintide/Metreleptin Combination Treatment for Obesity 5Cepheid Schedules 2009 Second Quarter Financial Results Announcement and Webcast 2Study on keeping nuclear bombs from US ports shows misplaced fear over cargo scanning cost 2Study on keeping nuclear bombs from US ports shows misplaced fear over cargo scanning cost 3Study on keeping nuclear bombs from US ports shows misplaced fear over cargo scanning cost 4
(Date:4/6/2015)... OXFORD, Conn. , Apr. 6, 2015 /PRNewswire/ ... the "Company"), a biometric authentication company focused on ... it has filed provisional patent 62/143028 for ... CLOSE-PROXIMITY COMMUNICATIONS AND ENERGY TRANSFER  NXT-ID introduces ... wireless payments. This patent surrounds the use of ...
(Date:4/2/2015)... 2, 2015 According to preliminary ... to somewhat higher than 125 MSEK. This exceeds the ... 2014 that revenues for Q1 2015 would be in ... for Q4 2014. The operating result for the first ... complete interim report will as previously communicated be published ...
(Date:4/1/2015)...   Medisafe ™, the leading global medication management ... and Android smartphones and tablets, announces ... platform to allow patients to track and correlate their ... patients will be able to visualize in real-time how ... such as glucose levels and blood pressure. ...
Breaking Biology News(10 mins):NXT-ID Patents Miniature, Low Power Wireless Magnetic Stripe 2NXT-ID Patents Miniature, Low Power Wireless Magnetic Stripe 3NXT-ID Patents Miniature, Low Power Wireless Magnetic Stripe 4Fingerprint Cards Revises Revenues for Q1 2015 2Medisafe Announces Launch of Biometric Integration, Enabling Patients to Stay Adherent to Their Meds and See Tangible Health Results 2
... Jackson Laboratory, in collaboration with Seoul National University, will ... Korean government for a large-scale cancer genomics project employing ... that can host human tumors. "This is ... is building to rapidly advance its research mission, in ...
... technique of intracellular particle tracking (simultaneous tracking of ... organelles, virions and even individual molecules), that is ... applications in search for appropriate medicines against certain ... no undeniable winner. Techniques proposed by all ...
... to the Italian biochemist Elena Conti, Director of the Department ... in Munich (Germany) and to Denis Le Bihan, the French ... the French Nuclear and Renewable Energy Commission (CEA) at Saclay ... CHF 700,000 for each of the two 2014 prizes, of ...
Cached Biology News:$7.5 million to JAX from South Korean government for cancer genomics project 29 and 60 ways of particle tracking 29 and 60 ways of particle tracking 32014 Louis-Jeantet Prize for Medicine 22014 Louis-Jeantet Prize for Medicine 32014 Louis-Jeantet Prize for Medicine 42014 Louis-Jeantet Prize for Medicine 5
Applications: Epitope mapping, Mapping protein-protein contacts, Identification of enzyme substrates/inhibitors, Identification of receptor agonists/antagonists...
quantitation of phosphatase activity, evaluation of hits and leads from HTS...
Bethyl Laboratories packages antibodies, conjugates and calibrators to provide quantitative ELISA kits. Each kit contains the following components, sufficient for 1000 single well assays....
... Quality ISO 9001:2000 Certified USDA ... Precedures Validated, SOP's Training AALAS ... for All Procedures GLP Documentation Upon Request ... stop shopping point for all your custom ...
Biology Products: